MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

51.29 +0.03 (+0.06%)
Streaming Delayed Price Updated: 3:59 PM EDT, May 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
36 37 Next >
News headline image
Volume Springs Back Into The OTC Markets In March – Take A Look At Some Of The Top Movers ↗
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Trading volume appears to be moving back to OTC Markets... 
Via Benzinga
News headline image
Read Why Pliant Therapeutics Shares Are Soaring Today ↗
Pliant Therapeutics Inc (NASDAQ: PLRX) says that with just two FDA-approved Idiopathic Pulmonary Fibrosis drugs, it believes that is a high unmet need. 
Via Benzinga
News headline image
The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Halozyme Buys Specialty Product Company Antares In $960M Deal 
Via Benzinga
News headline image
Why Are ImmunoGen Shares Trading Lower Today ↗
ImmunoGen Inc (NASDAQ: IMGN)  
Via Benzinga
News headline image
Healthcare Stocks Lead the Way Up as the Market Fades ↗
With inflation and energy costs soaring, the Fed ever threatening with higher rates and headlines from the war in Ukraine investors are seeking more defensive positions. 
Via Talk Markets
News headline image
BioNTech And Matinas BioPharma Announce Exclusive Research Collaboration To Evaluate Novel Delivery Technology For mRNA-based Vaccines ↗
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. 
Via Benzinga
News headline image
Recession Fears are Creating a Golden Opportunity for Biotech Stocks ↗
Biotech stocks are hard for novice investors to successfully profit from, but it's worth your time to learn the techniques now. 
Via InvestorPlace
News headline image
How Medicare 'Snuffed Out' Hope For Biogen's Controversial Alzheimer's Drug ↗
Only Medicare patients enrolled in specific studies will receive reimbursement. 
Via Investor's Business Daily
News headline image
Good and Bad stock news ↗
Microsoft is down because of an FTC investigation of its possible anti-competitive moves. 
Via Talk Markets
News headline image
New Data for Genentech’s Ocrevus (ocrelizumab) Show Benefit in Disability Progression and Cognitive Decline in Both Secondary Progressive and Primary Progressive Multiple Sclerosis
From Genentech
Via Business Wire
News headline image
SoftBank Loses Vision Fund Leader; Continues To Liquidate Portfolio ↗
Ron Fisher looked to depart as the head of SoftBank Group Corp's (OTC: SFTBY) (OTC: SFTBF) Vision Fund and Chair and director of SoftBank Investment Advisors U.S.... 
Via Benzinga
News headline image
Genentech's Ocrevus Shows Benefit In Disability Progression & Cognitive Decline In Multiple Sclerosis ↗
 
Via Benzinga
News headline image
FDA Grants Priority Review To Roche's Actemra For Hospitalized COVID-19 Adults ↗
 
Via Benzinga
News headline image
U.S. FDA Grants Priority Review to Genentech’s Actemra for the Treatment of COVID-19 in Hospitalized Adults
From Genentech
Via Business Wire
News headline image
Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates ↗
Biopharma stocks are sensitive to a key binary event called the PDUFA date, the date by which the Food and Drug Administration is required to give its verdict on a regulatory application filed with... 
Via Benzinga
News headline image
Roche's Tiragolumab Immunotherapy Flunks In Late-Stage Lung Cancer Trial ↗
Roche Holding AG's (OTC: RHHBY) Phase 3 SKYSCRAPER-02 study in extensive-stage small-cell lung cancer (ES-SCLC)  
Via Benzinga
News headline image
The Daily Biotech Pulse: Roche's Lung Cancer Combo Therapy Flunks Late-Stage Study, Adagio Spikes On Positive COVID Antibody Data, Amylyx Awaits Adcom Verdict ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
News headline image
Genentech Provides Update on Phase III SKYSCRAPER-02 Study in Extensive-Stage Small Cell Lung Cancer
From Genentech
Via Business Wire
News headline image
Biotech Funds and ETFs Continue to Lag ↗
It’s no secret that market sectors driving inflation are leading the market. With the US economy still strong and the War in Ukraine limiting supply of nat gas and raw materials, producer costs are... 
Via Talk Markets
News headline image
Drug makers, Scientists Working For Long COVID Treatments: Reuters ↗
Researchers and drugmakers, including those who have launched antiviral pills and monoclonal antibodies for COVID-19, are having early discussions about targeting Long COVID,  
Via Benzinga
News headline image
The Daily Biotech Pulse: MEI Pharma Wilts On Adverse Regulatory Development, Decision Day For Zogenix, AN2 Therapeutics IPO ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
News headline image
Flood Helping Ukraine ↗
Emerging markets are gaining as mature markets look risky. 
Via Talk Markets
News headline image
How Rivals Merck, Bristol Myers Benefit From Eli Lilly's FDA Snag ↗
The Food and Drug Administration on Thursday rejected a lung cancer drug Eli Lilly tested only in China, but LLY stock inched higher. 
Via Investor's Business Daily
News headline image
Up On Bad News ↗
Despite the plane crash in China, Boeing's stock is up today. 
Via Talk Markets
News headline image
World Markets News For Friday ↗
Buoyant global markets are closing the week and one good performer, Vir Biotech, today gained an impressive 6.09%. 
Via Talk Markets
News headline image
Roche's Evrysdi Shows Long-Term Efficacy, Safety In Broader Spinal Muscular Atrophy Population ↗
 
Via Benzinga
News headline image
Apellis Pharma Nears Breakout As Biotech Plots Its Blockbuster Filing ↗
If approved, this would be the company's second drug to hit the U.S. market. 
Via Investor's Business Daily
News headline image
New Data for Genentech’s Evrysdi (risdiplam) Demonstrate Long-Term Efficacy and Safety in a Broad Population of People With Spinal Muscular Atrophy (SMA)
From Genentech
Via Business Wire
News headline image
The OTCQX's Top 10 Experience A Shuffle In February ↗
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. 
Via Benzinga
News headline image
The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
36 37 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story